OBJECTIVE: To explore the relationships between serum concentrations of tissue inhibitor of metalloproteinase-2 (TIMP-2) and matrix metalloproteinase-2 (MMP-2), and severity of liver fibrosis in chronic hepatitis B. METHODS: A total of 101 patients with hepatitis B and 54 healthy control subjects were consecutively enrolled. Serum MMP-2 and TIMP-2 were quantified by enzyme-linked immunosorbent assay. RESULTS: Serum MMP-2 concentrations in patients with stage F2 -F4 fibrosis were significantly higher than in patients with stage F0 -F1 fibrosis and control subjects, but no significant difference was found between patients with stage F0 -F1 fibrosis and control subjects. Significant differences in serum TIMP-2 concentrations were found between patients with stages F2 -F4 and F0 -F1 fibrosis, and between stages F0 -F1 fibrosis and healthy control subjects. Areas under the receiver operating characteristic curves of serum TIMP-2 and MMP-2 for predicting clinically significant fibrosis (stage F2 -F4) were 0.899 and 0.770, respectively. CONCLUSION: Serum TIMP-2 and MMP-2 assessment may represent a valuable noninvasive diagnostic test for liver fibrosis in hepatitis B.
Introduction
Chronic hepatitis B may progress to significant liver fibrosis in some patients. It is important to detect fibrosis at an early stage in order to prevent cirrhotic complications or reverse any fibrosis using antifibrotic strategies. 1 Current clinical practice is to base the treatment decision on the stage of fibrosis found on liver biopsy. 2 Liver biopsy is the gold standard procedure to assess liver fibrosis and guide therapeutic decisions, but biopsy has several limitations including morbidity, mortality, 3, 4 sampling error resulting from the patchy distribution of liver B Liang, Y Li, A Zhao et al. Serum MMP-2 and TIMP-2 predict liver fibrosis fibrosis, 5 -7 reluctance of patients to undergo repeat biopsies and interobserver variation. 1 In addition, liver biopsy provides a static view of disease that does not reflect the balance between fibrogenesis and fibrolysis. 8 There is, therefore, a need for noninvasive and readily applicable methods for the assessment of liver fibrosis.
Liver fibrosis is a dynamic process involving extracellular matrix (ECM) deposition and degradation. 8, 9 Matrix metalloproteinases (MMPs) are a group of ECM degradation enzymes, and the balance between the concentrations of secreted MMPs and their specific inhibitors (tissue inhibitors of metalloproteinases [TIMPs]) plays an important role in maintaining connective tissue homeostasis in normal tissue. 10, 11 An imbalance between the activities of MMPs and TIMPs is thought to be linked to the process of liver fibrosis, 12 and serum MMP-2 and TIMP-2 levels may, therefore, represent noninvasive predictive markers of liver fibrosis.
The aim of this study was to investigate whether serum MMP-2 and TIMP-2 concentrations, without knowledge of liver biopsy findings, can be used to predict the extent of liver fibrosis in Chinese patients with biopsy-confirmed fibrosis due to chronic hepatitis B infection. 
Patients and methods

STUDY POPULATION
SERUM MMP-2 AND TIMP-2 ELISA
Venous blood was collected from each participant, allowed to clot for 1 h at room temperature, and centrifuged at 1600 g for 15 min at 4°C. Serum was frozen at -20°C within 2 h of collection. Serum concentrations of MMP-2 and TIMP-2 were determined using enzyme-linked immuno sorbent assay (ELISA) kits (human MMP-2 and human TIMP-2 Biotrak™ ELISA systems; GE Healthcare Life Sciences, Shanghai, China). Both kits were based on a solid ELISA sandwich format and were used according to the manufacturer's instructions. Optical density at 450 nm was read in a microtitre plate spectrophotometer (Thermo Multiskan MK3, Thermo Fisher Scientific, Shanghai, China). MMP-2 and TIMP-2 concentrations were obtained by interpolation from a standard curve. 
BIOCHEMICAL ASSESSMENT OF LIVER FUNCTION
LIVER BIOPSY HISTOLOGY
Liver tissue was obtained with a 16-gauge Klatskin needle using either a blind or ultrasound-guided technique. All liver biopsy specimens were ≥ 10 mm in length and at least five portal tracts were sampled. Tissue was fixed in 10% neutral buffered formalin, dehydrated in graded concentrations of ethanol, cleared in xylene and embedded in paraffin. Sections (4 -5 µm thick) were stained with haematoxylin and eosin for microscopy observation. A pathologist who was unaware of the biochemical results evaluated fibrosis according to the METAVIR system. 13 Fibrosis was graded on a scale of F0 -F4: F0, no fibrosis; F1, portal fibrosis without septa; F2, periportal fibrosis with few septa; F3, septal fibrosis with many septae; F4, probable or definite cirrhosis. As recommended by the American Association for the Study of Liver Disease practice guidelines, 14 clinically significant liver fibrosis was defined as a METAVIR fibrosis score ≥ 2 (F2 -F4).
STATISTICAL ANALYSES
The study used two endpoints: (i) clinically significant fibrosis (F2 -F4); (ii) no fibrosis or mild fibrosis (F0 -F1). The AST-platelet ratio index (APRI score) was determined using the following formula:
APRI score = AST of AST upper limit × 100 sample of normal 15 
Platelet count
The Mann-Whitney U-test and the Kruskal-Wallis test were used to assess differences between the groups. All tests were two-tailed. The diagnostic values of individual markers were assessed and compared by receiver operating characteristic (ROC) curve analysis, and the optimum cutoff levels of the different markers for significant fibrosis were obtained. The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the different markers were calculated. Tests were interpreted in parallel and in serial combinations.
Statistical analyses were performed using SPSS ® software, version 13.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . A P-value < 0.05 was considered statistically significant.
Results
The study enrolled 101 patients with chronic hepatitis B and 54 healthy control subjects. The characteristics of the study participants are shown in Table 1 . There were significant between-group differences in ALT, AST, APRI score, MMP-2, TIMP-2 (P < 0.01 for all comparisons) and platelet count (P < 0.05). There were no significant differences in age, gender, body mass index, serum albumin or serum total protein concentrations.
Serum MMP-2 concentrations were significantly higher in stage F2 -F4 patients (n = 54) compared with stage F0 -F1 patients (n = 47) and controls (P < 0.01 for both comparisons; Fig. 1A ); there was no significant difference between stage F0 -F1 patients and healthy controls. The ROC curves for serum MMP-2, TIMP-2, APRI score, HA, LN, PIIINP and CIV in the prediction of clinically significant fibrosis are shown in Fig. 2 . The area under the ROC curves was 0.899 (95% confidence interval [CI] 0.834, 0.963) for serum TIMP-2, 0.770 (95% CI 0.676, 0.864) for MMP-2, 0.749 (95% CI 0.561, 0.773) for APRI score, 0.609 (95% CI 0.497, 0.721) for HA, 0.746 (95% CI 0.652, 0.841) for LN, 0.641 (95% CI 0.532, 0.750) for PIIINP and 0.613 (95% CI 0.502, 0.723) for CIV. Table 2 shows the sensitivity, specificity, PPV and NPV of MMP-2, TIMP-2 and APRI score in predicting clinically significant fibrosis. Serum TIMP-2 was more powerful in identifying clinically significant fibrosis than serum MMP-2 or APRI score.
The diagnostic performance of parallel interpretations of TIMP-2 with MMP-2 and TIMP-2 with APRI was higher than when using each marker alone ( Table 3 ). Parallel 
Discussion
Liver fibrosis is the result of the excessive accumulation of ECM components. 12 The interactions between MMPs and their inhibitors are important in the deposition and degradation of ECM (collagen in particular) in liver fibrosis. 16 The present study examined the roles of MMP-2 and TIMP-2 because their mRNA expression has been previously shown to be increased in diseased fibrotic human liver specimens. 17, 18 Matrix metalloproteinase-2 promotes the proliferation of hepatic stellate cells, which are the main producers of ECM components. 19 Circulating MMP-2 concentrations are correlated with hepatic concentrations of the enzyme. 16 It is, therefore, tempting to speculate that liver MMP-2, as reflected by its circulating concentrations, might serve as a marker for fibroproliferation in chronic liver disease. Previous studies have reported contradictory findings regarding the relationship between serum MMP-2 and liver fibrosis, with evidence of a strong correlation, 20 weak correlation, 21 or no relationship 22 between these parameters. Others have reported that MMP-2 and TIMP-2 were unable to differentiate between mild and advanced liver fibrosis in children. 23 TIMP-2 is a specific inhibitor of MMP-2, 24 and an increase in TIMP relative to MMP is considered to be one 25 Molecular studies have demonstrated that increased expression of TIMP-2 mRNA in fibrotic human and rat liver -especially in hepatic stellate cellspromotes the progression of hepatic fibrosis by preventing collagen degradation. 26 Plasma levels of TIMP-2 have been shown to be related to the stage of liver fibrosis. 21 Serum MMP-2 concentrations were elevated in patients with clinically significant fibrosis (F2 -F4), but were similar in patients without fibrosis or with mild fibrosis (F0 -F1) and in healthy control subjects in the present study. In accordance with previous reports, 22,27 -29 serum TIMP-2 concentrations were elevated in line with increasing liver fibrosis in the present study. These differences in the estimation of the role of MMP-2 and TIMP-2 in liver fibrosis might be related to the use of different fibrosis scoring systems, as well as multiple versus single pathologists scoring the biopsies, 30 or different methods of grouping patients.
Patients in the current study were divided into two groups based on the stage of fibrosis (mild [F0 -F1] or clinically significant [F2 -F4]), in order to evaluate the diagnostic value of serum MMP-2 and TIMP-2 concentrations. These groups were chosen because patients with clinically significant fibrosis are recommended to receive antiviral therapy, whereas patients with mild fibrosis need only be kept under close observation. 31 The diagnostic performances of MMP-2 and TIMP-2 were compared with other markers of fibrosis (including APRI score, HA, LN, CIV and PIIINP), using ROC curves. ROC curves are used to determine a cut-off value for a clinical test 32 and are widely accepted as the standard for describing and comparing the accuracy of diagnostic tests. Serum tests that generate an area under the ROC curve for fibrosis of 0.85 -0.90 are considered to be useful markers. 1 In the current study, serum TIMP-2 generated an area under the ROC curve of 0.899, which was the highest of all the markers evaluated.
Common interpretation schemes for evaluating a combination of tests include parallel interpretation (which emphasizes sensitivity) and serial interpretation (which emphasizes specificity). 33 Combining two tests in the present study showed that parallel interpretation of TIMP-2 and MMP-2 had the highest sensitivity (96.4%), and serial interpretation of TIMP-2 and MMP-2 had the highest specificity (98.7%). These results demonstrate that serum TIMP-2 and MMP-2 concentrations can be used as screening tests for clinically significant fibrosis. If both TIMP-2 and MMP-2 are below the cut-off value (TIMP-2 < 60.2 ng/ml; MMP-2 < 2328 ng/ml), patients can be considered to be free from clinically significant fibrosis.
The costs of using serum MMP-2 and TIMP-2 as diagnostic markers are roughly equivalent to those for other liver fibrosis markers. Although liver biopsy is the gold standard for detecting liver fibrosis, it has several limitations, including poor patient tolerance. The requirement for regular monitoring of liver fibrosis has necessitated the development of noninvasive methods. Measuring serum MMP-2 and TIMP-2 produces immediate results and saves time, with the added advantages of improved feasibility and cost effectiveness.
The present study had several limitations. In common with other markers of liver fibrosis, 34 serum TIMP-2 and MMP-2 are not sufficiently specific: TIMP-2 is present in high levels in patients with aortic stenosis and other fibrosis-related diseases; 35, 36 MMP-2 has been found to be involved in the pathogenesis of pulmonary fibrosis. 37 The effect of other fibrosis-related diseases should, therefore, be considered when serum reference intervals for aspartate aminotransferase (AST), alanine aminotransferase (ALT) and γ-glutamyl transferase (GGT) in serum: results from an IFCC multicenter study. • Received for publication 1 November 2011 • Accepted subject to revision 11 November 2011 • Revised accepted 9 February 2012 Copyright © 2012 Field House Publishing LLP TIMP-2 and MMP-2 are used as markers for clinically significant liver fibrosis. In addition, the current study included a relatively small number of patients in a single geographical region of China. Larger, multicentre studies are required in order to gain further insight into the relationships between TIMP-2, MMP-2 and liver fibrosis.
In conclusion, this study demonstrated that serum TIMP-2 and MMP-2 concentrations could become valuable noninvasive diagnostic markers of liver fibrosis in chronic hepatitis B and may be considered indicators of clinically significant liver fibrosis. The use of a combination of serum TIMP-2 and MMP-2 tests could improve their sensitivity and specificity.
